Visualization of Nuclease- and Serum-Mediated Chromatin Degradation with DNA–Histone Mesostructures
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24043222 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Midori L Wasielewski und 6 weiteren Autor:innen. Beteiligte Einrichtung: Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA 30332, USA. Hauptthemen laut MEDLINE: Chromatin, Extracellular Traps. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NIH HHS, NHLBI NIH HHS.
Abstract (Originalsprache)
This study analyzed the nuclease- and serum-driven degradation of millimeter-scale, circular DNA–histone mesostructures (DHMs). DHMs are bioengineered chromatin meshes of defined DNA and histone compositions designed as minimal mimetics of physiological extracellular chromatin structures, such as neutrophil extracellular traps (NETs). Taking advantage of the defined circular shape of the DHMs, an automated time-lapse imaging and image analysis method was developed and used to track DHM degradation and shape changes over time. DHMs were degraded well by 10 U/mL concentrations of deoxyribonuclease I (DNase I) but not by the same level of micrococcal nuclease (MNase), whereas NETs were degraded well by both nucleases. These comparative observations suggest that DHMs have a less accessible chromatin structure compared to NETs. DHMs were degraded by normal human serum, although at a slower rate than NETs. Interestingly, time-lapse images of DHMs revealed qualitative differences in the serum-mediated degradation process compared to that mediated by DNase I. Importantly, despite their reduced susceptibility to degradation and compositional simplicity, the DHMs mimicked NETs in being degraded to a greater extent by normal donor serum compared to serum from a lupus patient with high disease activity. These methods and insights are envisioned to guide the future development and expanded use of DHMs, beyond the previously reported antibacterial and immunostimulatory analyses, to extracellular chromatin-related pathophysiological and diagnostic studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA 30332, USA.
- The Parker H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, GA 30332, USA.
- Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA.
- Biointerfaces Institute, University of Michigan, Ann Arbor, MI 48105, USA.
ORCID-Profile: Midori L Wasielewski, Katherine Nguyen, Shuichi Takayama
Förderung
- NIGMS NIH HHS
- NIH HHS
- NHLBI NIH HHS
- NIBIB NIH HHS
- NIH
- NIH-sponsored Research Training Program in Immuno-engineering
- HEERF III
Zitieren
APA
Wasielewski, M. L., Nguyen, K., Yalavarthi, S., Ekbote, P., Weerappuli, P. D., Knight, J. S., & Takayama, S. (2023). Visualization of Nuclease- and Serum-Mediated Chromatin Degradation with DNA–Histone Mesostructures. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24043222
Vancouver
Wasielewski ML, Nguyen K, Yalavarthi S, Ekbote P, Weerappuli PD, Knight JS, et al. Visualization of Nuclease- and Serum-Mediated Chromatin Degradation with DNA–Histone Mesostructures. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24043222
BibTeX
@article{Wasielewski2023,
author = {Wasielewski, Midori L and Nguyen, Katherine and Yalavarthi, Srilakshmi and Ekbote, Pallavi and Weerappuli, Priyan D and Knight, Jason S and Takayama, Shuichi},
title = {Visualization of Nuclease- and Serum-Mediated Chromatin Degradation with DNA–Histone Mesostructures},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24043222}
}
EUVIMED